
News|Articles|February 3, 2025
Data-Driven Insights can Optimize Clinical Trial Site Selection
Author(s)PurpleLab
Clinical trials are crucial for drug development but often face delays due to poor site selection, which can lead to protocol violations, poor data quality, and increased costs. Ninety percent of clinical trials fail to meet their timelines, and issues like inadequate staffing and patient recruitment are significant challenges. Traditional site selection methods are inefficient, and the COVID-19 pandemic has further complicated the process. Data-driven insights can optimize site selection by evaluating current data on patient populations, investigators, and site capabilities.
Trending on Applied Clinical Trials Online
1
FDA Reaffirms GCP Standards Amid Growing Concerns Over Foreign Clinical Trial Data
2
Beyond Patient Centricity: What Rare Disease Research Gets Right
3
Fortrea to Acquire Worldwide Clinical Trials' Early Phase Services Division in $45 Million Deal
4
AI Moves Patient Recruitment from Trial Bottleneck to Competitive Edge: A 2026 Perspective
5